[Link 1]


 [Link 2]
 [Link 3]

Standard myelofibrosis drug can awaken "dormant" lymphoma

JAK2 inhibitors awaken "dormant" lymphomas in the bone marrow and hence cancer as shown by a close cooperation of researchers of MedUni Vienna and and our research group. (Sabrina Tripolt, Andrea Hölbl-Kovacic et al.)

Link to press release [Link 4]

Link to article in Blood [Link 5]



 [Link 6]

New publication in Cancer Discovery

The team around Florian Bellutti and Veronika Sexl show astounding new insights of Cdk6 contribution to tumor formation focusing on Cdk6, p53 and p53 antagonist interactions.

Link [Link 7]


see full news archive [Link ]




Welcome to the Institute of Pharmacology and Toxicology



 [Link 8]

Our mission is to discover molecular mechanisms underlying physiological and pathophysiological processes in the organism. This approach is the base for rational drug design, it serves target identification and target validation in modern pharmacological research. Thereby our research offers hope for defeating some of humanity's most devastating diseases-- cancer. The mission of the institute is to perform research and education in molecular, cellular, and clinical pharmacology.

Modern medicine relies on the correct, precise use of drugs. The development of novel therapeutics over the last decades enabled us to cure a wide range of diseases. Yet many aspects still prove difficult and are awaited to be solved! The greatest challenge of our time is to translate the knowledge gathered in this post-genomic era into practice for patient-tailored treatment options - a concept termed as Personalised or Precision Medicine. Pharmacology is not only committed to find out the mechanism of action of drugs but also assists in preparing and understanding how modern drugs can be optimally exploited for the benefit of each patient in the future.

Curriculum Vitae of Veronika Sexl [Link 9]

Research [Link 10]

Publications [Link 11]


Recent publications


Florian Bellutti, Veronika Sexl, et al.
CDK6 Antagonizes p53-Induced Responses during Tumorigenesis [Link ]
Journal: Cancer Discovery


Agnieszka Witalisz-Siepracka, Dagmar Gotthardt, et al.
NK cell-specific CDK8 deletion enhances antitumor responses [Link 12]
Journal: Cancer Immunology Research


Leo Edlinger, Angelika Berger-Bečvař, et al.
Expansion of BCR/ABL1+ cells requires PAK2 but not PAK1 [Link 13]
Journal: British Journal of Haematology



Office: Mon. - Fri. 08:00-14:00

Student affairs: Mon. and Wed. 09:00-11:00

Tel: +43 1 25077 2901
Fax: +43 1 25077 2990
Email: Secretariat [Link 14]

Postal address:

Veterinary University of Vienna
Institute of Pharmacology and Toxicology
Veterinärplatz 1
1210 Vienna

Building HA, 3rd floor

Link to directions [Link 15]


Appointment with Veronika Sexl only after prior agreement per email: veronika.sexl(at)vetmeduni.ac.at [Link 16]